<DOC>
	<DOCNO>NCT02170935</DOCNO>
	<brief_summary>To determine PK profile single dose 150 mg BIBR 1048 , oral capsule , administer 1-3 hour post surgery hip replacement patient .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Assessment BIBR 1048 Patients After Primary Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patients schedule undergo primary elective total hip replacement Male female 18 year old ( woman child bear potential may include ) Patients weigh least 40 kg Written inform consent participation Bleeding disorder , e.g . history intracranial , intraocular , gastrointestinal pulmonary bleeding , know thrombocytopenia , history haemorrhagic stroke Known renal disease Known liver disease , alcohol drug misuse Known malignancy Treatment another study drug past month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>